Filing Flows › ADC Therapeutics SA (ADCT) › Q2 2026 › vs Q1 2026
ADC Therapeutics SA (ADCT) Q2 2026 vs Q1 2026 (quarter over quarter)
ADC Therapeutics SA's revenue fell $1.6M (-8%) from $20.9M in Q1 2026 to $19.2M in Q2 2026. The biggest changes: Product revenues, net −$1.4M (-7%); Royalties −$204K (-25%).
ADC Therapeutics SA, Q2 2026: revenue $19.2M (+2% year over year), operating margin -132.0%, net loss $16.6M, operating cash flow −$11.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Product revenues, net | $18.6M | $20.0M | −$1.4M | -7% |
| Royalties | $614K | $818K | −$204K | -25% |
| Revenue | $19.2M | $20.9M | −$1.6M | -8% |
| Other income, net | $8.8M | −$7.7M | $16.6M | — |
| Net loss | $16.6M | $33.0M | −$16.4M | -50% |
| Costs & expenses | $44.7M | $53.8M | −$9.2M | -17% |
| Operating costs | $44.7M | $46.1M | −$1.4M | -3% |
| Research & development | $17.4M | $19.9M | −$2.5M | -13% |
| Sales & marketing | $12.6M | $12.7M | −$136K | -1% |
| General & admin | $9.7M | $9.9M | −$195K | -2% |
| Other operating costs | $5.0M | $3.6M | $1.4M | +39% |
| Operating cash sources | $16.6M | $33.0M | −$16.4M | -50% |
| Share-based compensation | $4.5M | $2.4M | $2.1M | +86% |
| Working capital & other | $208K | $816K | −$608K | -75% |
| Cash used in operations | $11.8M | $29.7M | −$17.9M | -60% |
| Net loss absorbed | $16.6M | $33.0M | −$16.4M | -50% |
Questions
How much did ADC Therapeutics SA's revenue grow quarter over quarter in Q2 2026?
ADC Therapeutics SA's revenue fell $1.6M (-8%) from $20.9M in Q1 2026 to $19.2M in Q2 2026.
What drove ADC Therapeutics SA's revenue change in Q2 2026?
Product revenues, net −$1.4M (-7%); Royalties −$204K (-25%).